Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000300972—referred to as "novel transcript, sense intronic to ABHD2"—is a putative long non-coding RNA transcript that is annotated as being located within an intron of the ABHD2 gene. There is no evidence that this transcript encodes a functional protein, nor is it recognized as an established biological or therapeutic target. It does not have a canonical gene symbol, known aliases, or classified molecular function. No disease associations, biomarkers, or interacting drugs have been reported for this entry, and there is insufficient information to infer molecular or pharmacological characteristics[5]. This entry is not a recognized protein, receptor, enzyme, or therapeutic target; it is a generic, unnamed lncRNA and should not be used as a canonical target designation[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, sense intronic to ABHD2 (ENSG00000300972).